Pro Medicus

(AI video summary)

This video was created on 13 February 2026 for IG audiences by ausbiz.

ASX code: PME

Pro Medicus navigates market turbulence

Pro Medicus shares extended their selloff today after a sharp fall following the release of its record half‑year results. Despite posting strong revenue and profit growth, the stock reaction has been negative, with the share price now down about 60% over the past 

Dr Sam Huppert, chief executive officer (CEO) and founder of Pro Medicus, addressed the market concerns by stating that the reported profit figure included a $10 million investment in 4D Medical. Excluding this, the net profit after tax (NPAT) increased approximately 30%. Dr Huppert also dismissed concerns that artificial intelligence (AI) could negatively impact the business, emphasising AI’s alignment with Pro Medicus's strategic growth.

AI viewed as a long‑term tailwind

Analysts argue the Visage platform is designed to integrate AI tools directly into a radiologist’s workflow, improving speed and accuracy. Because Pro Medicus offers a unified imaging and AI environment, radiologists are unlikely to shift to external applications. Its per‑scan billing model is also expected to remain viable even as AI takes on greater analysis tasks over time.

Investment outlook

Pro Medicus continues to trade on elevated multiples, with the company valued at about 90 times earnings. However, analysts maintain that the business consistently earns operating profit margins of about 73%, among the highest on the ASX 200.